Opioid Use Disorder (OUD) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Opioid Use Disorder (OUD) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Opioid Use Disorder (OUD) Market

The Opioid Use Disorder (OUD) market size was valued at USD 3.35 billion in 2023, and the market is now projected to grow from USD 3.62 billion in 2024 to USD 7.48 billion by 2032, exhibiting a CAGR of 9.5% during the forecast period of 2023-2030.

The COVID-19 pandemic created significant opportunities on the Opioid Use Disorder (OUD) market growth as curbing coronavirus outbreak was prioritized. Discontinuing the branded drug partly motivated the customers to visit the generic facility to resolve their ailments and generate sales. Therefore, some products in the pharmaceutical industry experienced a sharp decline in demand. Therefore, the authorities have been forced to declare a national lockdown made of both internal and external expectorations of the contaminated part of the town or country in order to control the escalating rates of the pandemic. Similarly, there was a huge decrease in the number of patients who attended hospitals. Not only non-essential medical operations have been cancelled or delayed, but they have also been blamed as services that widened the market.

The Opioid Use Disorder (OUD) market share globally has been contributed due to the growing opioid addiction cases. The whole planet inhabitants face a variety of serious and contemporary health issues, including cardiovascular disorders, cancer and other afflictions, which is actively occurring today. They are the main agent of these curative drugs. Painkillers, in mostly the opioids are unfolded. In most cases, drug use culminates in drug addiction in patients, which is the second reason why drug use should be restricted to healthcare professionals. The patient’s withdrawal symptoms will might be due to the patients gaining dependency to these drugs and the unplanned cessation of them.

Furthermore, there’s been a notable trend of increasing consideration of buprenorphine patches as an effective treatment mode. During the last few months the market had been growing, taking along with it a growing demand for buprenorphine patches. To overcome the addiction, these patches are proven to act as an effective intervention. With convenience of transdermal patches and one may choose adherent if it might be the best option to make medication delivery.

Comprehensive Analysis of Opioid Use Disorder (OUD) Market

The Opioid Use Disorder (OUD) market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by types of drug class, route of administration, and distribution channel. The drug class types include, methadone, buprenorphine, and naltrexone. However, the route of administration is such as oral and parenteral.

The North American region is conducive to the global Opioid Use Disorder (OUD) market, leading to a recall of USD 2.59 billion owing to increased opioid dependency. Subsequently, a good number of Americans dealing with opioid dependency, various players in the region, as well as the intensified participation of the local governments in the fight against opioid crisis are the main factors that contributed to the growth of the industry.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Indivior PLC (U.S.), Alkermes (Ireland), Orexo AB (Sweden), Titan Pharmaceuticals, Inc. (U.S.), Mallinckrodt Pharmaceuticals (U.K.), BioDelivery Sciences International Inc. (U.S.), Viatris Inc. (Mylan N.V.) (U.S.), Hikma Pharmaceuticals PLC (U.K.), and Camurus (Sweden) these market players provide a level-playing competitive landscape.

In July 2023 Orexo AS reported that the Company got patent litigation against Sun Pharmaceutical Industries Limited for product ZUBSOLV in US.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 9.5% from 2024-2032

Unit Value (USD Billion)

Segmentation By Drug Class

Buprenorphine

Methadone

Naltrexone

By Route of Administration

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies & Stores

Online Pharmacies

By Region

North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country)

U.S.

Canada

Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)

U.K.

Germany

France

Italy

Spain

Scandinavia

Rest of Europe

Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)

Japan

China

India

Australia

South East Asia

Rest of Asia Pacific

Rest of the World (By Drug Class, By Route of Administration, By Distribution Channel)